TOKYO & BASKING RIDGE, N.J., December 22, 2025--(BUSINESS WIRE)--The first patient has been dosed in the DESTINY-Endometrial02 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) with or ...
DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...
Study further expands clinical development program of Bayer’s long-acting reversible intrauterine system Mirena® (levonorgestrel-releasing intrauterine system) 52 mg. Approximately 121 out of every ...
Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically ...
“Following the positive results in the endometrial cancer cohort of DESTINY-PanTumor02, which contributed to a tumor agnostic approval for previously treated patients with HER2 positive metastatic ...
As GSK races to match its PD-1 blocking antibody Jemperli to Merck’s superstar Keytruda, new pivotal data could help it expand into a broader endometrial cancer population. Jemperli, used on top of ...
The MarketWatch News Department was not involved in the creation of this content. Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for ...
Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer Adding cisplatin to doxorubicin ...
NEWTOWN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback